Dr Bruno Paiva speaks to cancer at the 2019 MyKE Myeloma meeting about the latest technological advances in assessing a patient's MRD status.
Despite being high-risk for myeloma at the time of diagnosis, these patients may be MRD negative after treatment - in which Dr Paiva describes the risk as being "dynamic".
He discusses how the use of next-generation flow/sequencing and PET/CT scans have improved the assessment of MRD; in which flow cytometry and ASO-PCR methods have been used in the past.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.